Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma

PURPOSE: Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability. It inhibits signaling through the PI3/AKT axis and other cascades of biologic importance in glioblastoma, and has promising pre-clinical activity in vitro and in vivo. Therefore, we conduc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Neurooncol
Asıl Yazarlar: Kaley, Thomas J., Panageas, Katherine S., Mellinghoff, Ingo K., Nolan, Craig, Gavrilovic, Igor T., DeAngelis, Lisa M., Abrey, Lauren E., Holland, Eric C., Lassman, Andrew B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7493746/
https://ncbi.nlm.nih.gov/pubmed/31325145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-019-03243-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller